Researchers sought to determine whether mosunetuzumab would have long-term efficacy in patients with follicular lymphoma.

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

As Fedoriw and Dogan note in their 2016 review, “Follicular lymphoma is a far more heterogeneous entity than originally appreciated." 2 At a recent workshop in Istanbul, Turkey arranged by the ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

Follicular lymphoma (FL) is the second most common form of NHL ... inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. This indication is approved under accelerated approval based on response rate ...

The new use is the third for Kymriah (tisagenlecleucel) in the EU and offers patients with grade 1, 2 and 3A follicular lymphoma that has returned after two or more prior treatments a new ...